U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Paradoxical increased cortisol secretion on dexamethasone suppression test

MedGen UID:
369358
Concept ID:
C1968855
Finding
HPO: HP:0003466

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVParadoxical increased cortisol secretion on dexamethasone suppression test

Conditions with this feature

Pigmented nodular adrenocortical disease, primary, 1
MedGen UID:
400627
Concept ID:
C1864846
Disease or Syndrome
Primary pigmented nodular adrenocortical disease (PPNAD) is a form of ACTH-independent adrenal hyperplasia resulting in Cushing syndrome. It is usually seen as a manifestation of the Carney complex (CNC1; 160980), a multiple neoplasia syndrome. However, PPNAD can also occur in isolation (Groussin et al., 2002). Genetic Heterogeneity of Primary Pigmented Nodular Adrenocortical Disease See also PPNAD2 (610475), caused by mutation in the PDE11A gene (604961) on chromosome 2q31; PPNAD3 (614190), caused by mutation in the PDE8B gene (603390) on chromosome 5q13; and PPNAD4 (615830), caused by a duplication on chromosome 19p13 that includes the PRKACA gene (601639).
Pigmented nodular adrenocortical disease, primary, 2
MedGen UID:
355843
Concept ID:
C1864851
Disease or Syndrome
Any primary pigmented nodular adrenocortical disease in which the cause of the disease is a mutation in the PDE11A gene.

Recent clinical studies

Diagnosis

Araujo-Castro M, Marazuela M
Front Endocrinol (Lausanne) 2022;13:913253. Epub 2022 Aug 5 doi: 10.3389/fendo.2022.913253. PMID: 35992106Free PMC Article
Huang W, Molitch ME
Semin Nephrol 2021 Mar;41(2):156-167. doi: 10.1016/j.semnephrol.2021.03.010. PMID: 34140094
Burman P, Lethagen A, Ivancev K, Johansson L, Sundin A
Eur J Endocrinol 2008 Oct;159(4):483-8. Epub 2008 Jul 14 doi: 10.1530/EJE-08-0385. PMID: 18625689
Ujihara M, Yoshimoto T, Cho R, Totsuka Y, Imaki T, Nomura K, Nishikawa T, Takano K
Endocr J 2001 Feb;48(1):19-23. doi: 10.1507/endocrj.48.19. PMID: 11403099
Hána V, Dokoupilová M, Marek J, Plavka R
Clin Endocrinol (Oxf) 2001 Feb;54(2):277-81. doi: 10.1046/j.1365-2265.2001.01055.x. PMID: 11207645

Therapy

Hána V, Dokoupilová M, Marek J, Plavka R
Clin Endocrinol (Oxf) 2001 Feb;54(2):277-81. doi: 10.1046/j.1365-2265.2001.01055.x. PMID: 11207645

Prognosis

Tung SC, Hwang DY, Yang JW, Chen WJ, Lee CT
Endocr J 2012;59(9):823-30. Epub 2012 Jun 20 doi: 10.1507/endocrj.ej12-0040. PMID: 22785148

Clinical prediction guides

Ujihara M, Yoshimoto T, Cho R, Totsuka Y, Imaki T, Nomura K, Nishikawa T, Takano K
Endocr J 2001 Feb;48(1):19-23. doi: 10.1507/endocrj.48.19. PMID: 11403099
Hána V, Dokoupilová M, Marek J, Plavka R
Clin Endocrinol (Oxf) 2001 Feb;54(2):277-81. doi: 10.1046/j.1365-2265.2001.01055.x. PMID: 11207645

Supplemental Content

Table of contents

    Clinical resources

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...